ABC | Volume 113, Nº4, October 2019

Updated Updated Cardiovascular Prevention Guideline of the Brazilian Society Of Cardiology – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 Table 11.4 – LDL-cholesterol targets in children and adolescents, according to cardiovascular risk profile LDL-cholesterol levels Risk < 190 mg/dL Without another risk factor < 160 mg/dL Early coronary insufficiency in the family Or other risk factor < 130 mg/dL Established coronary insufficiency OR 2 diseases or high risk factors OR 1 disease OR high risk factor AND 2 diseases or moderate risk factors (Table 11.3) Table 11.5 – Medicines used to treat dyslipidemia in childhood and adolescence Medicine Dose Observations Lovastatin, pravastatin, simvastatin and atorvastatin 10-40 mg/day Pravastatin for HIV and atorvastatin for HF (> 7years) Rosuvastatin 5-20 mg/day Mainly in HF (> 7 years) Cholestyramine 4-16 g/day Any age Ezetimibe 10 mg/day > 4 years old Bezafibrate, fenofibrate 200-600 mg/day TG persistently > 500 mg/dL Omega 3 2-4 g/day Variable effect Phytosterols 1,2-1,5 g/day Variable effect Table 11.3 – Reference values for lipids and lipoproteins in children and adolescents Lipids Fasting (mg/dL) Not fasting (mg/dL) Total cholesterol < 170 < 170 HDL-cholesterol > 45 > 45 Triglycerides (0-9 years old) (10-19 years old) < 75 < 90 < 85 < 100 LDL-cholesterol < 110 < 110 Non-HDL-cholesterol > 145 > 145 Adapted from “Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report”. 858